The winner will be announced in the coming months! Follow Bioanalysis Zone on Twitter, Facebook or LinkedIn to be the first to find out the winner!
Nominated by: Zhiyu Li, WuXi AppTec (Shanghai, China)
“It is my great honor to support Dr. Sen Cheng’s nomination for the Bioanalysis Rising Star Award. She is a dedicated young scientist who has an unrelenting pursuit of excellence in the field of bioanalysis. After her graduation from Peking University in November, 2019, I had the delight to recruit Sen into my New Capability Building Team. In just six months, she not only established a new LC-MS based oligo bioanalysis platform, but also trained several junior scientists and formed an oligo analysis team. Her team developed oligo bioanalysis methods for more than 20 different biological matrices, four animal species, and three types of delivery systems. Her work supported in vitro and in vivo screenings, and IND filings for multiple oligo drugs. Besides, her scientific support and training for colleagues in other departments, including Toxicology and GLP Bioanalysis, further facilitated preclinical and clinical trials for our clients. She has won Excellent Scientist Award in DMPK for her work. In the meanwhile, Sen has been an active writer and presenter to share her scientific discoveries and experience, to the benefit of the wider bioanalysis community. I believe she will bring greater contributions to our bioanalytical communities in the future.”
Describe the main highlights of your bioanalytical work.
During doctoral years, my work focused on the application of LC-MS-based proteomics to examine the landscape of pathogen and host protein expression during infection. I firstly reported a novel Salmonella effector via dimethyl labeling quantitative profiling and named it SopF (Cheng S, Molecular & Cellular Proteomics, 2017). In addition, I apply IP-MS analysis and ADP-ribosylproteome to further investigate the molecular mechanism of SopF and its ADP-ribosylated substrate during infection (Cheng S, Cell, 2019). This work provided an innovative insight into cell biological processes and signal pathways by using MS-based platform, which is now expanding its interface role to the diverse research areas of life science and bioanalysis.
After joining WuXi AppTec, within a year, me and my team have established comprehensive oligo-based platforms including LC-MS, qPCR, and LC-Fluorescence, which have delivered multiple robust and sensitive bioanalytical methods for more than 20 oligonucleotide projects from early discovery to clinical phase. This platform filled the gaps for WuXi AppTec DMPK department and provided integrated methodology for Oligo bioanalysis. A better assay sensitivity and throughput was produced on this platform when compared with the reported results, and the bioanalysis of Oligo used to belong to challenged category has now become as routine in WuXi AppTec DMPK.
[Video edit by Andrew McKinnon]
In association with